These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 31481034)

  • 21. Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and International Index of Erectile Function-5 questionnaires.
    Nakamura M; Fujimura T; Nagata M; Hosoda C; Suzuki M; Fukuhara H; Enomoto Y; Nishimatsu H; Kume H; Igawa Y; Homma Y
    Aging Male; 2012 Jun; 15(2):111-4. PubMed ID: 22283118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of systemic atherosclerosis on overactive bladder symptoms in men with benign prostatic hyperplasia.
    Lee D; Koo KC; Yoo JW; Lee KS
    Low Urin Tract Symptoms; 2022 Jan; 14(1):35-40. PubMed ID: 34323012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
    Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
    Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of peripheral zone thickness in men with lower urinary tract symptoms/benign prostatic hyperplasia.
    Kwon JK; Han JH; Choi HC; Kang DH; Lee JY; Kim JH; Oh CK; Choi YD; Cho KS
    BJU Int; 2016 Feb; 117(2):316-22. PubMed ID: 25807886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
    Chughtai B; Dunphy C; Lee R; Lee D; Sheth S; Marks L; Kaplan SA; Te AE
    Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].
    Wada N; Hashidume K; Tamaki G; Kita M; Iwata T; Matsumoto S; Kakizaki H
    Hinyokika Kiyo; 2012 Sep; 58(9):475-80. PubMed ID: 23070385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
    Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms.
    Kosilov K; Loparev S; Kuzina I; Shakirova O; Zhuravskaya N; Lobodenko A
    Aging Male; 2017 Mar; 20(1):39-44. PubMed ID: 28074677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Five-year outcomes of thulium vapoenucleation of the prostate for symptomatic benign prostatic obstruction.
    Gross AJ; Orywal AK; Becker B; Netsch C
    World J Urol; 2017 Oct; 35(10):1585-1593. PubMed ID: 28405763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.
    Takeda M; Nishizawa O; Gotoh M; Yoshida M; Takahashi S; Masumori N
    Urology; 2013 Oct; 82(4):887-93. PubMed ID: 23953605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
    Nozawa Y; Kato D; Tabuchi H; Kuroishi K
    Low Urin Tract Symptoms; 2018 May; 10(2):122-130. PubMed ID: 27860325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostatic artery embolization for prostate volume greater than 80 cm3: results from a single-center prospective study.
    Kurbatov D; Russo GI; Lepetukhin A; Dubsky S; Sitkin I; Morgia G; Rozhivanov R; Cimino S; Sansalone S
    Urology; 2014 Aug; 84(2):400-4. PubMed ID: 24929948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder.
    Irwin DE; Milsom I; Kopp Z; Abrams P; Artibani W; Herschorn S
    Eur Urol; 2009 Jul; 56(1):14-20. PubMed ID: 19278775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of holmium laser enucleation of prostate on overactive bladder symptoms and urodynamic parameters: a prospective study.
    Kwon O; Lee HE; Bae J; Oh JK; Oh SJ
    Urology; 2014 Mar; 83(3):581-5. PubMed ID: 24373317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BiVap saline vaporization of the prostate in men with benign prostatic hyperplasia: our clinical experience.
    Karakose A; Aydogdu O; Atesci YZ
    Urology; 2014 Mar; 83(3):570-5. PubMed ID: 24275275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates.
    Wang M; Guo L; Duan F; Yuan K; Zhang G; Li K; Yan J; Wang Y; Kang H
    BJU Int; 2016 Jan; 117(1):155-64. PubMed ID: 25851432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study.
    Chuang YC; Liu SP; Lee KS; Liao L; Wang J; Yoo TK; Chu R; Sumarsono B
    Low Urin Tract Symptoms; 2019 Jan; 11(1):48-55. PubMed ID: 28967230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
    Utsunomiya N; Matsumoto K; Tsunemori H; Muguruma K; Kawakita M; Kamiyama Y; Kanamaru S; Ito N; Tsukazaki H; Shirahase T; Takahashi T
    Hinyokika Kiyo; 2016 Jul; 62(7):341-7. PubMed ID: 27569351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.
    Matsuo T; Miyata Y; Kakoki K; Yuzuriha M; Asai A; Ohba K; Sakai H
    BMC Urol; 2016 Jul; 16(1):45. PubMed ID: 27473059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.